Top Takes From RealMoney

The RealMoney contributors are in the business of trading and investing all day on the basis of ongoing news flow. Below, we offer the top five ideas that RealMoney contributors posted today and how they played those ideas.

TheStreet.com brings you the news all day, and with RealMoney's "Columnist Conversation," you can see how the pros are playing it on a real-time basis. Here are the top five ideas played today. To see all that RealMoney offers, click here for a free trial.

Ford Secondary

By Daniel Dicker
05/13/09 8:14 a.m.

Priced rather aggressively (for a Goldman offering!) at $4.75. It's trading in the premarket right about there. If you are a true believer in the Ford (F) story -- (the only remaining legitimate American car company, best leadership, cars people still want to buy)-- now's your chance. Lotsa stock out there, and a lot of syndicate players who will be happy to dump for a dime (or less!).

Me? Yeah, I'm buying. YMMV!

Positions: Long F

Medicines Co.

By Adam Feuerstein
05/13/09 9:14 a.m.

A few readers have asked me if hit being taken by Medicines Co.(MDCO Quote) is an overreaction.

No.

The blood-thinner Cangrelor was the only potential growth driver for the company. Now that it's gone, so is Medicines Co. The company will continue to sell Angiomax into the cath lab market, but the drug is going off patent and will face generic competition next year. Cleviprex, a blood pressure drug, has been a dud since launch last year and the experimental antibiotic oritavancin is a joke.

I was short MDCO in the Biotech Select model portfolio but covered awhile ago for a 50% gain. I had my doubts about Cangrelor. Damn, I covered too early.

Positions: None